Life Benefits Gearing up for the Last 3-day Wealth Summit

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Life Benefits Gearing up for the Last 3-day Wealth Summit of 2014 in Minneapolis

SALEM, Ore., Aug. 12, 2014 (GLOBE NEWSWIRE) -- via PRWEB - Life Benefits has provided financial education from a unique perspective to individuals, families and business owners across the United States for over 7 years. This year in addition to online resources at http://www.life-benefits.com , Life Benefits launched a 3-day Wealth Summit first held in San Diego and now coming to Minneapolis September 12-14th.

"The San Diego Summit was a huge success", says Event Coordinator Michele McFie, "we can't wait for Minneapolis. There are already more people registered for Minneapolis at this point then there were for San Diego so that's a great indication people love the 3-day high-energy format."

After the Wealth Summit in San Diego former NFL player Slade Norris said, "This conference was invaluable to me. It's something that I think everyone should do more than once […] I really had a great time."

Topics to be covered at the Minneapolis Wealth Summit include: Exterminating $91,200.04 of credit card debt within 11 months, Beating the Bankers, Business Financing, Myth Busting, The Power of NOW, Developing a Wealthy Mindset, and How to finance eight $40,000 Cars for less than $1 per day.

Life Benefits is also pleased to announce a special guest speaker for the Minneapolis Wealth Summit: Rabbi Daniel Lapin author of Thou Shall Prosper, and host of the Rabbi Daniel Lapin Radio show on KSFO. Another special guest speaker is tentative but not yet confirmed.

A major focus of Life Benefits' educational efforts is the unique power of Participating Whole Life Insurance as a financial tool. "Many people today ridicule whole life insurance as a 'bad investment', but it wasn't always that way. History shows it to be a great financial foundation if structured correctly," says Tom McFie President of Life Benefits, "It provides a basis of guarantees, liquidity and protection which can't be found anywhere else. In these economic times that is what people are wanting."

Note: Loans and withdrawals from life insurance can cause adverse tax consequences, penalties and may cause a policy to lapse. Insurance products are backed by the claims paying ability of the issuing insurance company and are not FDIC insured. Life Benefits, Inc., its agents, and representatives are not authorized to give legal or tax advice.

For more information about the 3-Day Wealth Summit in Minneapolis September 12th-14th contact Ben McFie at 1-866-502-2777 or visit: http://www.life-benefits.com/wp/minneapolis-2...th-summit/

Ben McFie, Director of Public Relations
Life Benefits, Inc.
Office: 1-866-502-2777
http://www.life-benefits.com

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2014/08/prweb12080629.htm

Life Benefits, Inc. Ben McFie +1 866-502-2777

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 41

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 36

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 32

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 37

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Growth of Middle-Class Investors through Mutual Fund Ownership

Updated Category News Views 149

Mutual Funds and the Rise of the Middle-Class Investor Over recent years, mutual fund ownership has surged among middle-class families. According to insights from the Investment Company Institute (ICI), this trend signifies a vital transition as middle-income households increasingly seek investment opportunities. The growing presence of mutual funds in the American...

Continue Reading
Rques Exchange Reinforces Its Brand with Compliance Strategy

Updated Category News Views 180

Rques Exchange Reinforces Brand with Regulatory Frameworks Rques Exchange is taking significant steps to enhance its brand by emphasizing its commitment to regulatory alignment, operational transparency, and governance integrity in various markets. With global authorities increasingly scrutinizing digital asset platforms, Rques aims to position itself as a technology...

Continue Reading
Business Growth and Confidence: Provident Bank's Insights

Updated Category News Views 120

Increasing Business Confidence for the Future Recently, Provident Bank, a prominent financial institution based in New Jersey, conducted an enlightening Economic Outlook survey. This survey reflects the sentiments of 1,000 business leaders regarding the 2025 economic prospects. The results showcase a robust sense of optimism and confidence among businesses as they look...

Continue Reading
Performance Food Group Co: A Five-Year Stock Journey

Updated Category News Views 219

Unlocking the Value of Investment in Performance Food Group Co Performance Food Group Co (NYSE: PFGC) has delivered impressive returns over the last five years, standing out in the competitive market landscape. With an annualized return that has surpassed the market by 9.42%, investors have seen an average growth rate of around 24.5%. This stock is not just another entry...

Continue Reading
Understanding Rathbones Group Plc's Disclosure Requirements

Updated Category News Views 227

Key Information on Disclosure Requirements Understanding how companies disclose their shareholding is crucial for investors and stakeholders alike. Rathbones Group Plc plays an essential role in managing these disclosures, particularly regarding relevant securities that represent substantial interests in listed companies. Full Name of the Discloser The full name of the...

Continue Reading